Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Unknown 1Completed 1

Sponsor Class

OTHER 6NIH 2INDUSTRY 2OTHER_GOV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Lymphoid 2Breast 1

Conditions

Lymphoma, Non-Hodgkin 767Lymphoma 713Leukemia, Lymphocytic, Chronic, B-Cell 560Lymphoma, Follicular 515Lymphoma, Large B-Cell, Diffuse 440Precursor Cell Lymphoblastic Leukemia-Lymphoma 331Recurrence 317Lymphoma, B-Cell 294Neoplasms 261Lymphoma, Mantle-Cell 251Leukemia 231Multiple Myeloma 189Hodgkin Disease 179Leukemia, Myeloid, Acute 178Lymphoma, B-Cell, Marginal Zone 135Lymphoma, T-Cell, Peripheral 119Burkitt Lymphoma 105Myelodysplastic Syndromes 101Hematologic Neoplasms 100Lymphoma, T-Cell, Cutaneous 88Waldenstrom Macroglobulinemia 84Leukemia, B-Cell 79Lymphoma, T-Cell 74Leukemia, Myelogenous, Chronic, BCR-ABL Positive 65Lymphoproliferative Disorders 57Hematologic Diseases 57Melanoma 54Carcinoma, Non-Small-Cell Lung 54Breast Neoplasms 51Mycosis Fungoides 49

Interventions

siltuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Castleman Disease × Lymphoid × Clear all
NCT00412321 2014-07-01

A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease

Centocor, Inc.

Phase 1 Completed
67 enrolled
LymphoidPlasma cell

Castleman Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT00891280 2011-06-15

Dose-escalation Study of Oral CX-4945

Cylene Pharmaceuticals

Phase 1 Unknown
55 enrolled
BreastLymphoidPlasma cell

Breast Neoplasms, Castleman Disease, Multiple Myeloma, Inflammatory Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡